Loomis, Sayles & Company
MIRM icon

Loomis, Sayles & Company’s Mirum Pharmaceuticals MIRM Stock Holding History

Loomis, Sayles & Company’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.9M Sell
443,636
-31,688
-7% -$3.18M 0.07% 110
2026
Q1 		$43.9M Sell
475,324
-39,657
-8% -$3.73M 0.06% 114
2025
Q4 		$40.7M Sell
514,981
-24,059
-4% -$1.73M 0.05% 132
2025
Q3 		$39.5M Sell
539,040
-13,917
-3% -$885K 0.05% 138
2025
Q2 		$28.1M Sell
552,957
-13,198
-2% -$588K 0.04% 184
2025
Q1 		$25.5M Sell
566,155
-11,869
-2% -$559K 0.04% 202
2024
Q4 		$23.9M Buy
578,024
+78,708
+16% +$3.28M 0.03% 228
2024
Q3 		$19.5M Buy
+499,316
New +$19.9M 0.03% 259

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company's MIRM Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its Mirum Pharmaceuticals (MIRM) stake by 6.7% in Q2 2026, selling an estimated $3.18M and leaving 443,636 shares worth $51.9M. The position accounts for 0.07% of the portfolio, ranked #110.

Loomis, Sayles & Company first reported a position in MIRM in Q3 2024 and has held it in 8 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Loomis, Sayles & Company held 443,636 shares of Mirum Pharmaceuticals worth $51.9M as of Q2 2026.
  • Loomis, Sayles & Company sold 31,688 Mirum Pharmaceuticals shares in Q2 2026, an estimated $3.18M.
  • Mirum Pharmaceuticals made up 0.07% of Loomis, Sayles & Company's portfolio in Q2 2026, its #110 holding.
  • Loomis, Sayles & Company first reported a position in Mirum Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.